Note 8 - Accrued Expenses

12 Months Ended

Dec. 31, 2024

Notes to Financial Statements

Accrued Expenses [Text Block]

Note 8. Accrued Expenses

Accrued expenses consisted of the following (in thousands):

	December 31,
	2024		2023
Legal expenses	$	81	$	102
Offering costs		1,356		1,356
Compensation and related benefits		35		43
Other accrued expenses		76		232
Accrued expenses	$	1,548	$	1,733

The product warranty accrual related to the voluntary recall of DABRA catheters was initiated in September 2019. The recall was closed by the FDA in July 2023 and no claims have been submitted in approximately 2 years. As such, the Company derecognized the warranty liability of $192 thousand as of December 31, 2023. The accrued warranty balance was $0 as of December 31, 2024 and 2023.